Astaxanthin inhibits proliferation and induces apoptosis of LX‑2 cells by regulating the miR‑29b/Bcl‑2 pathway

Zhu,Shanshan; Wang,Tao; Luo,Fei; Li,Huawen; Jia,Qing; He,Taiping; Wu,Hongfu; Zou,Tangbin

doi:10.3892/mmr.2019.10025

Astaxanthin inhibits proliferation and induces apoptosis of LX‑2 cells by regulating the miR‑29b/Bcl‑2 pathway

Authors:
- Shanshan Zhu
- Tao Wang
- Fei Luo
- Huawen Li
- Qing Jia
- Taiping He
- Hongfu Wu
- Tangbin Zou
View Affiliations

Affiliations: Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, Guangdong 523808, P.R. China, Department of Surgery, The Third Affiliated Hospital of Guangdong Medical University, Longjiang Hospital of Shunde District, Foshan, Guangdong 528318, P.R. China, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong 523808, P.R. China
Published online on: March 14, 2019 https://doi.org/10.3892/mmr.2019.10025
Pages: 3537-3547
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of microRNAs (miRNAs/miRs) in the anti‑fibrotic effect of astaxanthin (AST), using the human hepatic stellate cell (HSC) line LX‑2 as the research model. LX‑2 cells were treated with various concentrations of AST (10, 20 and 40 µM) for 24 or 48 h. miR‑29b was selected based on existing literature, and its targeting gene B cell lymphoma (Bcl)‑2 was predicted by TargetScan and miRanda databases for further analysis. Interactions between miR‑29b and Bcl‑2 in the AST treated LX‑2 cells were evaluated using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis. MTT analysis was used to analyze cell viability. Overexpression of miR‑29b decreased the expression of Bcl‑2 in AST‑treated LX‑2 cells, and silencing of it had the opposite effect. Additionally, Annexin V‑fluorescein isothiocyanate/propidium iodide double staining and flow cytometry were used to evaluate the cell apoptosis, and overexpression of miR‑29b increased cell apoptosis rates in AST‑treated LX‑2 cells; however, silencing of it had the opposite effect. RT‑qPCR and western blotting demonstrated that AST induced LX‑2 cells apoptosis which may be by regulating miR‑29b, as indicated by inhibited Bcl‑2 expression levels and elevated Bax and Caspase‑3 expression levels. These results highlight an important role of miR‑29b in the AST modulating LX‑2 cells proliferation and apoptosis and implicate a potential mechanism of miR‑29b and AST preventing liver fibrosis.

View Figures

View References

1	Sun M and Kisseleva T: Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 39 (Suppl 1):S60–S63. 2015. View Article : Google Scholar : PubMed/NCBI
2	Carloni V, Luong TV and Rombouts K: Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: More complicated than ever. Liver Int. 34:834–843. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhang CY, Yuan WG, He P, Lei JH and Wang CX: Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
4	Campana L and Iredale JP: Regression of liver fibrosis. Semin Liver Dis. 37:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zoubek ME, Trautwein C and Strnad P: Reversal of liver fibrosis: From fiction to reality. Best Pract Res Clin Gastroenterol. 31:129–141. 2017. View Article : Google Scholar : PubMed/NCBI
6	Puche JE, Saiman Y and Friedman SL: Hepatic stellate cells and liver fibrosis. Compr Physiol. 3:1473–1492. 2013. View Article : Google Scholar : PubMed/NCBI
7	Elpek GÖ: Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol. 20:7260–7276. 2014. View Article : Google Scholar : PubMed/NCBI
8	Singh TR, Gupta A and Suravajhala P: Challenges in the miRNA research. Int J Bioinform Res Appl. 9:576–583. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wu Q, Yang Z, Shi Y and Fan D: MiRNAs in human cancers: The diagnostic and therapeutic implications. Curr Pharm Des. 20:5336–5347. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhou B, Li Z, Yang H and He N: Extracellular miRNAs: Origin, function and biomarkers in hepatic diseases. J Biomed Nanotechnol. 10:2865–2890. 2014. View Article : Google Scholar : PubMed/NCBI
11	He Y, Huang C, Sun X, Long XR, Lv XW and Li J: MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal. 24:1923–1930. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zheng J, Lin Z, Dong P, Lu Z, Gao S, Chen X, Wu C and Yu F: Activation of hepatic stellate cells is suppressed by microRNA-150. Int J Mol Med. 32:17–24. 2013. View Article : Google Scholar : PubMed/NCBI
13	Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, Wu J and Zern MA: Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol. 298:G101–G106. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kitano M and Bloomston PM: Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis. J Clin Med. 5:E382016. View Article : Google Scholar : PubMed/NCBI
15	He Y, Huang C, Zhang SP, Sun X, Long XR and Li J: The potential of microRNAs in liver fibrosis. Cell Signal. 24:2268–2272. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ambati RR, Phang SM, Ravi S and Aswathanarayana RG: Astaxanthin: Sources, extraction, stability, biological activities and its commercial applications-a review. Mar Drugs. 12:128–152. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chen JT and Kotani K: Astaxanthin as a potential protector of liver function: A review. J Clin Med Res. 8:701–704. 2016. View Article : Google Scholar : PubMed/NCBI
18	Higuera-Ciapara I, Félix-Valenzuela L and Goycoolea FM: Astaxanthin: A review of its chemistry and applications. Crit Rev Food Sci Nutr. 46:185–196. 2006. View Article : Google Scholar : PubMed/NCBI
19	Fakhri S, Abbaszadeh F, Dargahi L and Jorjani M: Astaxanthin: A mechanistic review on its biological activities and health benefits. Pharmacol Res. 136:1–20. 2018. View Article : Google Scholar : PubMed/NCBI
20	Guerin M, Huntley ME and Olaizola M: Haematococcus astaxanthin: Applications for human health and nutrition. Trends Biotechnol. 21:210–216. 2003. View Article : Google Scholar : PubMed/NCBI
21	Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, et al: Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 53:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Edlich F: BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochem Biophy Res Commun. 500:26–34. 2018. View Article : Google Scholar
24	Kisseleva T and Brenner DA: Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 22 (Suppl 1):S73–S78. 2007. View Article : Google Scholar : PubMed/NCBI
25	Yang Y, Kim B, Park YK, Koo SI and Lee JY: Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. Biochim Biophys Acta. 1850:178–185. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zou TB, Jia Q, Li HW, Wang CX and Wu HF: Response surface methodology for ultrasound-assisted extraction of astaxanthin from Haematococcus pluvialis. Mar Drugs. 11:1644–1655. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhang XS, Zhang X, Zhou ML, Zhou XM, Li N, Li W, Cong ZX, Sun Q, Zhuang Z, Wang CX and Shi JX: Amelioration of oxidative stress and protection against early brain injury by astaxanthin after experimental subarachnoid hemorrhage. J Neurosurg. 121:42–54. 2014. View Article : Google Scholar : PubMed/NCBI
28	Guo SX, Zhou HL, Huang CL, You CG, Fang Q, Wu P, Wang XG and Han CM: Astaxanthin attenuates early acute kidney injury following severe burns in rats by ameliorating oxidative stress and mitochondrial-related apoptosis. Mar Drugs. 13:2105–2123. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ravi Kumar S, Narayan B, Sawada Y, Hosokawa M and Miyashita K: Combined effect of astaxanthin and squalene on oxidative stress in vivo. Mol Cell Biochem. 417:57–65. 2016. View Article : Google Scholar : PubMed/NCBI
30	Shen M, Chen K, Lu J, Cheng P, Xu L, Dai W, Wang F, He L, Zhang Y, Chengfen W, et al: Protective effect of astaxanthin on liver fibrosis through modulation of TGF-β1 expression and autophagy. Mediators Inflamm. 2014:9545022014. View Article : Google Scholar : PubMed/NCBI
31	Böttcher K and Pinzani M: Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev. 121:3–8. 2017. View Article : Google Scholar : PubMed/NCBI
32	Schuppan D and Kim YO: Evolving therapies for liver fibrosis. J Clin Invest. 123:1887–1901. 2013. View Article : Google Scholar : PubMed/NCBI
33	Bansal R, Nagorniewicz B and Prakash J: Clinical advancements in the targeted therapies against liver fibrosis. Mediators Inflamm. 2016:76297242016. View Article : Google Scholar : PubMed/NCBI
34	Tutar L, Tutar E and Tutar Y: MicroRNAs and cancer; an overview. Curr Pharm Biotechnol. 15:430–437. 2014. View Article : Google Scholar : PubMed/NCBI
35	Shin VY and Chu KM: MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
36	Feng B, Zhang K, Wang R and Chen L: Non-small-cell lung cancer and miRNAs: Novel biomarkers and promising tools for treatment. Clin Sci (Lond). 128:619–634. 2015. View Article : Google Scholar : PubMed/NCBI
37	Song SJ and Pandolfi PP: MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Curr Opin Hematol. 21:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
38	Kaboli PJ, Rahmat A, Ismail P and Ling KH: MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 97:104–121. 2015. View Article : Google Scholar : PubMed/NCBI
39	Fiserova B, Kubiczkova L, Sedlarikova L, Hajek R and Sevcikova S: The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 159:184–191. 2015. View Article : Google Scholar : PubMed/NCBI
40	Liang C, Bu S and Fan X: Suppressive effect of microRNA-29b on hepatic stellate cell activation and its crosstalk with TGF-β1/Smad3. Cell Biochem Funct. 34:326–333. 2016. View Article : Google Scholar : PubMed/NCBI
41	Wang J, Chu ES, Chen HY, Man K, Go MY, Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget. 6:7325–7338. 2015.PubMed/NCBI
42	Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB and Yang JR: The role of miR-29b in cancer: Regulation, function, and signaling. Onco Targets Ther. 8:539–548. 2015.PubMed/NCBI
43	Li J, Dai W, Xia Y, Chen K, Li S, Liu T, Zhang R, Wang J, Lu W, Zhou Y, et al: Astaxanthin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells via inhibition of Nf-κb P65 and Wnt/β-catenin in vitro. Mar Drugs. 13:6064–6081. 2015. View Article : Google Scholar : PubMed/NCBI
44	Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI
45	Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI